GALACTIC-HF Shows Omecamtiv Mecarbil Brings Greater Benefits for Severe Heart Failure
Patients with lower ejection fraction see most improvement with experimental drug this ACC late-breaking study
The results of the GALACTIC-HF trial shows omecamtiv mecarbil offers benefits to severe heart failure patients.
May 18, 2021 The experimental heart failure drug omecamtiv mecarbil reduced heart failure hospitalizations by a greater margin among patients with more severely reduced ejection fraction compared with those who had moderately reduced ejection fraction. This was the finding of the GALACTIC-HF trial presented at the American College of Cardiology (ACC) 2021 scientific session.
Omecamtiv mecarbil works by improving the ability for heart muscle cells to contract and operates through a different biological pathway than any of the current heart failure medications. The research is an extended analysis of data from GALACTIC-HF, a trial involving more than 8,200 participants that fo
Novel IL-6 Antibody Slashes CRP up to 92% in High-risk ASCVD medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.
AI Able to Predict COVID-19 Mortality From Cardiac Ultrasound Measurements
Using artificial intelligence for LVEF and longitudinal strain minimized variability compared to human review in late-breaking ACC study
The WASE-COVID Study used the artificial intelligence automated echocardiogram reading software EchoGo-Core from Ultromics to evaluate ejection fraction and left ventricle longitudinal strain in COVID-19 patients to identify risk markers for mortality. The study also compared human vs. AI variability in assessing the exams.
May 18, 2021 Artificial intelligence (AI) derived heart measurements were able to predict COVID-19 (SARS-CoV-2) mortality on echocardiograms in an international cardiac ultrasound study of COVID-19 patients. The Echocardiographic Correlates of in-hospital Death in Patients with Acute COVID-19 Infection: The World Alliance Societies of Echocardiography (WASE-COVID) Study was presented at the American College of Cardiology (ACC) 2021 virtual Scientifi
FIDELIO-DKD: Finerenone Cuts New AF in Type 2 Diabetes and CKD medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.
Omecamtiv mecarbil significantly reduces hospitalizations among patients with severe heart failure
The experimental heart failure drug omecamtiv mecarbil reduced heart failure hospitalizations by a greater margin among patients with more severely reduced ejection fraction, a measure indicating severe impairment in the heart s pumping ability, compared with those who had moderately reduced ejection fraction, according to research presented at the American College of Cardiology s 70th Annual Scientific Session.
Omecamtiv mecarbil works by improving the ability for heart muscle cells to contract and operates through a different biological pathway than any of the current heart failure medications.
The research is an extended analysis of data from GALACTIC-HF, a trial involving more than 8,200 participants that found omecamtiv mecarbil significantly improved outcomes in terms of a composite of cardiovascular death or heart failure events among patients with heart failure with reduced e